NeuroEnergy Ventures Names George Stagnitti as CEO
George Stagnitti photo
George E. Stagnitti, Jr.

NEW YORK, NY March 4, 2024 – NeuroEnergy Ventures, Inc. has named George E. Stagnitti, Jr. as the company’s Chief Executive Officer.

Mr. Stagnitti, a highly experienced executive in the growing field of medical foods and targeted nutritional supplements, joins NeuroEnergy Ventures as the company prepares to launch its first product, an innovative medical food designed to maintain brain function in people with mild cognitive impairment and Alzheimer’s Disease.

“As our new CEO, George Stagnitti brings us a wealth of industry knowledge and technical skills as our firm advances from research and development into commercialization of our novel brain nutrition product,” said James du Lieu, president of NeuroEnergy Ventures.

Before joining NeuroEnergy Ventures, Mr. Stagnitti held senior leadership roles at Brightseed Bio, PanTheryx, Synthetic Genomics, Efficas, Martek Biosciences, and other businesses engaged in the development, production, and marketing of sophisticated nutritional products intended to enhance human health and wellbeing. His expertise encompasses the range of technologies and processes involved in creating, manufacturing, packaging, and distributing these products.

About NeuroEnergy Ventures, Inc.

Based in the United States, NeuroEnergy Ventures was founded in 2016 as a scientific philanthropy. From the beginning, the firm’s focus has been on research and development of ketone-based medical foods, foods for special dietary use and related compounds for people with reduced neuronal metabolism based on decades-long research.

In addition to its soon-to-be-announced new medical food, NeuroEnergy Ventures is exploring additional applications for its innovative approach to ketone-based brain nutrition.

The firm holds a large portfolio of patents covering its medical food and related biomedical innovations. These include 38 granted patents and 23 pending patent applications for glyceride esters used in the treatment of diseases associated with reduced neuronal metabolism of glucose and other medical indications.

Contact:

NeuroEnergy Ventures, Inc.
641 Lexington Avenue, 14th Floor
New York, NY 10022
+1 (212) 328-9524
gstagnitti@neuro-energy.com
neuro-energy.com